Moleculin Biotech (MBRX) · Annamycin / naxtarubicin + cytarabine
Later window · A neutral label from comparing the two stated windows. It says nothing about the program’s results.
Before
Stated timing: December 2026 to February 2027
Enrollment remains on track to reach the 90-patient milestone in September with the data readout in the December 2026 to February 2027 timeframe.
EX-99.1 · filed · SEC filing
After
Stated timing: Q1 2027
the trial on track for a comprehensive Q1 2027 readout
EX-99.1 · filed · SEC filing
Data as of . Both sentences are quoted from the SEC filings linked above and matched to them.
Source: ORION, orionbiotechai.com/changes/MBRX-annamycin-naxtarubicin-cytarabine-2026-09-29, data as of Oct 13, 2026
https://www.orionbiotechai.com/changes/MBRX-annamycin-naxtarubicin-cytarabine-2026-09-29
Moleculin Biotech (MBRX) pipeline and stated timing · Calendar · Companies A–Z